ASH 2023 | The current landscape of treatment for HR-MDS: an update from ASH 2023
Jacqueline Garcia
• 11 Dec 2023
Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the current landscape of treatment for higher-risk myelodysplastic syndromes (HR-MDS). Although transplantation is the gold standard, eligibility is limited for most patients. Ongoing clinical trials explore combinations of hypomethylating agents (HMAs), immunotherapies, small molecule inhibitors, and targeted therapies with the aim of enhancing survival outcomes and delaying progression to acute myeloid leukemia (AML). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
